Pharma Market Access Insights - from Petauri Evidence

EXPLORE

Society & Culture

Health & Fitness

© 2024 PodJoint

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/01/eb/01/01eb0117-bd8a-3808-0fc1-54e85d028d9e/mza_5094890008854355116.jpg/600x600bb.jpg

Pharma Market Access Insights - from Petauri Evidence

Petauri Evidence

71 episodes

3 days ago

Send us a text What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing? This episode explores Switzerland’s potential as an early launch market. In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Acces...

Show more...

Health & Fitness,

All content for Pharma Market Access Insights - from Petauri Evidence is the property of Petauri Evidence and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Send us a text What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing? This episode explores Switzerland’s potential as an early launch market. In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Acces...

Show more...

Health & Fitness,

Episodes (20/71)

Pharma Market Access Insights - from Petauri Evidence

First to Market: Unlocking Switzerland’s Pharma Potential

Send us a text What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing? This episode explores Switzerland’s potential as an early launch market. In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Acces...

3 days ago

44 minutes

Pharma Market Access Insights - from Petauri Evidence

Q&A Webinar: The Evolving NHS Landscape in England – From Policy to Practice

Send us a text In this NHS Whispers live Q&A webinar, Katie Mulholland (Senior Consultant, UK Market Access, Petauri Evidence) speaks to: - Sarah Everest Ford (Programme Director, Health and Care Partnership) - Patrick McGee (Deputy Programme Director for Pathology, Lancashire & South Cumbria) - Prof. Phil Richardson (Former Dorset ICS System Commissioning Director; now Chief Innovation Officer, Petauri Evidence) Together, they explore the implications of changing N...

1 month ago

1 hour

Pharma Market Access Insights - from Petauri Evidence

Global Pricing and Market Access – Strategies for Success in an Evolving Landscape

Send us a text Uncover the forces driving change in global pricing and access In this expert-led discussion we explore the latest trends, challenges, and strategic considerations shaping global pricing and market access (GPMA). At Petauri Evidence, our Global Pricing and Market Access Team are growing to meet the increasing complexity of global launch and access, bringing together fresh perspectives and decades of real-world experience. In this episode, our experts, Clare Foy and Adam Brown,...

4 months ago

52 minutes

Pharma Market Access Insights - from Petauri Evidence

Transforming Global Market Access: Smarter Resource Management with Local Affiliates

Send us a text Discover a smarter way to manage and share market access resources with local affiliates Are your global market access resources scattered, leading to inconsistencies and confusion among your affiliates? In this webinar we discussed how a centralised platform can streamline resource sharing, ensure access to nationally-relevant evidence, and put the resources your local affiliates need right at their fingertips. The webinar features a conversation with Tim Styche (Market Acces...

5 months ago

33 minutes

Pharma Market Access Insights - from Petauri Evidence

Communicating value to US Payers: Insights for Pharma and Medtech

Send us a text What do global market access teams need to know about the US market? What do US payers expect to hear from Pharma and Medtech companies? What kind of value messaging resonates in the US? How do you prepare for launch in a market as diverse as the US? In this Global Whispers episode, Louise Maddison (Senior Consultant – Global Market Access, Petauri Evidence) interviews some of our colleagues from Petauri Advisors who are either former payers, or former industry market access l...

6 months ago

59 minutes

Pharma Market Access Insights - from Petauri Evidence

Navigating market access: Launch strategies and health economic modelling for medical devices

Send us a text Discover how health economics can support successful Medical Device launch, proposition development, and market access This episode offers an insightful journey into the world of medical device market access. Specialists from our health economics and market access teams explore the hidden challenges faced by medical devices companies when taking new innovations to healthcare leaders, communicating value and demonstrating evidence, and offer tips on leveraging health economics ...

6 months ago

44 minutes

Pharma Market Access Insights - from Petauri Evidence

Navigating US payer evidence needs to optimise market access

What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market?In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges.We ...

11 months ago

57 minutes

Pharma Market Access Insights - from Petauri Evidence

Best practice RWE approaches to support economic modelling for HTA

How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison?Here, Mtech Access are joined by experts from Arcturis and Delta Hat. Dan Howard (Associate Director – Health Economics, Mtech Access) shares some of the challenges that our clients face when developing HTA-ready health economic models with limited clinical trial data. Joseph O’Reilly (Princip...

12 months ago

59 minutes

Pharma Market Access Insights - from Petauri Evidence

NHS winter planning 2024–25 – Engaging with NHS decision-makers through Autumn to Christmas

How is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months?In August, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by Jo Turl (Former Director of Commissioning, Devon ICS) to explore these challenges.Jo and Karen discuss:How ICBs and Directors of Commissioning prepare for winter pressuresThe current key areas of focus at Pla...

12 months ago

1 hour 2 minutes

Pharma Market Access Insights - from Petauri Evidence

De-mystifying the NHS – What you need to know about the NHS as a market for your health technology

Are you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a new health technology to the NHS in England? In July 2024, Global Whispers and NHS Whispers came together, to bring you an overarching view of what it takes to access the NHS with a medtech or pharmaceutical innovation.Guest speaker Dr Faris Al-Ramadani who shared his experience of introducing new technologies to the NHS fr...

1 year ago

56 minutes

Pharma Market Access Insights - from Petauri Evidence

NHS primary care panel – the GP Contract and Operational Planning Guidance

What can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future of primary care? What are the biggest challenges facing primary care in 2024–25?In this webinar, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) spoke to a panel of NHS Associates about the current state and future of primary care and what this means for industry. Our panellists were:- Jack Wagstaf...

1 year ago

1 hour 2 minutes

Pharma Market Access Insights - from Petauri Evidence

Engage NHS healthcare decision-makers with RWD

Discover how data visualisation dashboards can aid field teams in market access discussions with customers. Healthcare leaders look to real-world data (RWD) to inform decisions. Field teams presenting decision-makers with RWD within a well-designed, easy-to-use visualisation can build a case for change, while positioning themselves as a trusted partner. Watch this 20-minute discussion between Iain Shield (Associate Director – Market Access) and Ben Spurr (Head of Partnerships) to discover how...

1 year ago

20 minutes

Pharma Market Access Insights - from Petauri Evidence

Market access and reimbursement in Canada – changes at CADTH

What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025? In this webinar, Clare Foy (Director – Global Market Access, Mtech Access) interviewed Don Husereau (Adjunct Professor of Medicine, The University of Ottawa).We take a look at the market access, health policy, and health technology assessment in Canada. Clare Foy and Don Husereau explore:The m...

1 year ago

47 minutes

Pharma Market Access Insights - from Petauri Evidence

Rare Disease market access in the MENA and Nordic regions

Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region?In this webinar, our Global Market Access tea...

1 year ago

59 minutes

Pharma Market Access Insights - from Petauri Evidence

How does funding flow in NHSE Regions?

Which decisions are made at Region level in the NHS in England? How do finances and funding work at this level? And how can industry best support and engage with Region leaders?We sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion that explored finance, funding flows, system priorities, and the decision-making process in NHS Regions.Richard heads up system co-ordination work across the NHS So...

1 year ago

1 hour

Pharma Market Access Insights - from Petauri Evidence

NHS policy for 2024/25: strategy and engagement in a world of uncertainty (recorded in Jan 2024)

What do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on the horizon, how can NHS and industry drive forward improvements and innovation?Host Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by guest speakers Debbie Morgan (Director of Service Improvement and Transformation, Cambridge University Hospitals NHS Fo...

1 year ago

1 hour 2 minutes

Pharma Market Access Insights - from Petauri Evidence

De-mystifying health economic model classifications and structures

What is health economic evaluation and which modelling approaches can be used to support market access activities?In this episode, our expert health economists explain the key strengths and limitations of the most common health economic modelling classifications and structures. Here, Hannah Gillies (Consultant – Health Economics) and Daniel MacDonald (Associate Consultant – Health Economics) de-mystify the different approaches to health economic modelling.Our specialists explore six of the mo...

1 year ago

1 hour

Pharma Market Access Insights - from Petauri Evidence

Evidence strategy for Medical Technologies and Diagnostics

Here, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies.Have you established the clinical and economic value of your medical device, diagnostic or digital technology? Do you have the evidence required to support your value proposition? Would a health technology assessment (HTA) route be appropriate for your product? What will payers, HTA agencies, and other key decision makers be looking for? And how should this information be presented?I...

1 year ago

53 minutes

Pharma Market Access Insights - from Petauri Evidence

How to set your Pharma or Medtech product up for success in the US market

How can you ensure your product is set up for success from early clinical trials right through to launch and commercialisation? In this Global Whispers webinar we explore best practice commercialisation strategy for healthcare products launching in the US market.Clare Foy (Director – Global Market Access, Mtech Access) speaks to Janice MacLennan (Pharma and Medtech brand strategist and founder of NMBLR) about how market access, HEOR and commercialisation leads in Pharma and Medtech can best s...

1 year ago

43 minutes

Pharma Market Access Insights - from Petauri Evidence

What's happening with specialised commissioning in the NHS?

What’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty?Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) speaks to David Thorne (Principal Associate, Mtech Access) to explore specialised commissioning in the NHS and what to expect as we head into 2024.Malcolm Qualie and David Thorne explored:Specialised commissioning ...

1 year ago

1 hour